The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
5HT6 antagonists in the treatment of Alzheimer's dementia: current progress
Open accessAbstract
Alzheimer's disease is an important condition with a considerable and unmet disease burden in large need of continued research and more treatment options. The 5HT6 antagonists are a new class of medications to be offered. Because they are pro-cholinergic, these medications are to be used as adjuncts to acetylcholinesterase inhibitors (such as donepezil), further increasing acetylcholine in the central nervous system (CNS). Early trials of the 5HT6 antagonists showed improvements in cognition and activities of daily living when used as adjuncts to current therapies for Alzheimer's dementia. However, recent phase III trials have failed to show a statistically significant improvement in cognitive function. This article will provide a comprehensive review of 5HT6 antagonists in drug development, including some that have been recently discontinued. We will discuss both the successes and failures of this drug class and provide rationale for their continued research and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cholinesterase inhibitors have a useful, modest role in improving cognition and activities of daily living in patients with mild-to-moderate Alzheimer's disease and memantine can be prescribed in combination or each drug used separately for moderate and severe Alzheimer's disease.2, 199, 200”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 4×
“Their research has shown an association between the use of SSRIs and decreased amyloid-beta plaques in mice.”
BackgroundInfluentialSerotonergic Drugs: Effects on Appetite Expression and Use for the Treatment??of Obesity
Halford, J. C. G., Harrold, J. A., Boyland, E. J., Lawton, C. L., & Blundell, J. E. (2007) · Drugs · doi:10.2165/00003495-200767010-00004 · Cited by 307
Atri, A., Frölich, L., Ballard, C., Tariot, P. N., Molinuevo, J. L., Boneva, N., Windfeld, K., Raket, L. L., & Cummings, J. L. (2018) · JAMA · doi:10.1001/jama.2017.20373 · Cited by 167
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher‐Edwards, G., Dixon, R., Hunter, J. A., Gold, M., Hopton, G., Jacobs, G., Hunter, J., & Williams, P. M. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2562 · Cited by 113
Ferrero, H., Solas, M., Francis, P. T., & Ramírez, M. J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0399-3 · Cited by 112
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
5-HT6 receptors and Alzheimer's disease
Ramírez, M. J. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt169 · Cited by 103
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“Three 5HT6 antagonists and the calcium channel blocker nilvadipine 203,204 have also been ineffective.”
RetractedMultitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Metadata
- Authors
- Andrews, M., Tousi, B., & Sabbagh, M. N.
- Affiliations
- Creighton University (US)
- Cleveland Clinic (US)
- Corresponding author
- Sabbagh, Marwan N.
- Venue
- Neurology and Therapy
- Published
- 2018-05-02
- Volume
- 7
- Issue
- 1
- Pages
- 51-58
- ISSN
- 2193-6536 (ISSN-L)
- 2193-8253
- PMC
- PMC5990506
- OpenAlex
- W2800992605
- Cited by
- 50
- References
- 23
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 13 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 4 · 2018: 1
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Neurology and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Barrow Neurological Foundation (NIA P30 AG019610)
- National Institute on Aging (AG019610, P30AG019610)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- 5-HT6 receptor antagonists, Alzheimer's disease, Alzheimer's dementia, acetylcholinesterase inhibitors, donepezil, adjunctive therapy, cognitive function, activities of daily living, phase III trial failure, drug development, drug discontinuation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5HT6 antagonists in the treatment of Alzheimer's dementia: current progress. https://app.cochat.ai/papers/10.1007/s40120-018-0095-y
- The paper
- Andrews, M., Tousi, B., & Sabbagh, M. N. (2018). 5HT6 antagonists in the treatment of Alzheimer's dementia: current progress. Neurology and Therapy. https://doi.org/10.1007/s40120-018-0095-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.